Presenting at National Proton Conference

RNS Number : 8516B

Advanced Oncotherapy PLC

10 March 2014

 

10 March2014                                                                                                                                                 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

Advanced Oncotherapy to Present at National Proton Conference

Advanced Oncotherapy (AIM: AVO), the developer of innovative medical technology for cancer treatment, announces that they will be attending the second annual National Proton Conference in Pentagon City, Arlington, Virginia. The conference will run from 31 March to 3 April 2014.

Sanjeev Pandya, the COO of Advanced Oncotherapy, will be presenting a panel entitled 'The Changing Landscape of Proton Therapy: A Review of Development Strategies'.  This panel will discuss the technological development strategies in the delivery of radiation with protons. There will be an opportunity to talk about the proton beam therapy machine that is currently in development with Advanced Oncotherapy and how this differs from traditional cancer treatments.

The conference, sponsored by the National Association for Proton Therapy (NAPT) and the Proton Therapy Consortium is a three day annual event that will include presentations on the current state of proton therapy clinical trials and studies; the advantages of treating children with proton therapy; the economics of proton therapy; the steps involved in planning, developing and launching a proton therapy centre; innovations in design, equipment and engineering; treating breast, head and neck cancers with proton therapy and more. 

Michael Sinclair, CEO of Advanced Oncotherapy commented: "We are delighted that Sanjeev has been invited to present the Advanced Oncotherapy story at this major conference. This is one of the few conferences dedicated to proton therapy, and through our attendance we can gain important information from the world leaders in this technology. As a company, we are looking to simplify and reduce the cost of proton centres around the world and we look forward to sharing our ideas with like-minded individuals."

For more information on the NAPT, please go to http://www.proton-therapy.org/ 

For further information contact:

Advanced Oncotherapy Plc	www.avoplc.com
Michael Sinclair (CEO)	Tel: [phone]
Westhouse Securities	Tel: [phone]
Antonio Bossi (Nomad & Joint Broker)
David Coaten
Peterhouse Corporate Finance	Tel: [phone]
Jon Levinson (Joint Broker)
Lucy Williams
Walbrook PR
Anna Dunphy/Mike Wort (Financial PR & IR)	Tel: [phone] or [e-mail]

About Advanced Oncotherapy

Vision:

To advance patients' clinical treatments and improve their everyday lives by harnessing innovative science and focusing it to develop the most effective and affordable cancer treatments.

Mission:

To facilitate the wider use of radiation with protons for treating all forms of cancerous tumours by commercialising novel technologies inspired by CERN and the Large Hadron Collider

Key corporate messages:

1.    AVO's team based at CERN near Geneva focuses on the development of a proprietary proton system called Linac Image Guided Hadron Technology (LIGHT). This patented system accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and a quarter of the cost. This compact configuration delivers proton beams faster thereby facilitating greater precision and electronic control which is not achievable with older technologies.

2.    AVO is a provider of proton radiotherapy that harnesses the best in modern technology.  As a result, the Company will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology which is proven to bring better health outcomes and lower treatment related side effects. There are signed letters of intent to place to provide [8] LIGHT units around the world.

3.    AVO continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with these providers. Through these relationships the Company will remain the prime provider of innovative and cost-effective equipment for proton radiation. This will allow healthcare suppliers to access more cost effective and more efficient ways to treat the increasing number of cancer patients who expect lower short term and long term side effects of their cancer care. 

4.    AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT).  This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient.  It is currently available in the UK from Spire Healthcare and BMI Healthcare Hospitals.

5.    Through its shareholding and collaboration with Advanced Proton Solutions (APS), AVO can offer a complete turnkey solution to the design installation and operation of its LIGHT proton system for healthcare providers. This is attractive to potential purchasers and has led to its involvement in the development of the first comprehensive proton beam therapy centre in London to treat both NHS and private patients. 

For more information, please visit http://www.avoplc.com

 

END

 

 

NRAJRMJTMBJMTII